Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?

Stock Information for Sage Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sage Therapeutics Inc.

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders
Shareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates
Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm
Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025
SAGE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc. - SAGE
SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.